Rifaximin provides significant relief of irritable bowel syndrome symptoms

Jan 05, 2011
Yehuda Ringel, M.D., of the University of North Carolina at Chapel Hill, is a co-author of these two studies. Credit: UNC Medical Center News Office

A pair of clinical trials, conducted in part at the University of North Carolina at Chapel Hill, found that two weeks of treatment with rifaximin provides significant relief of irritable bowel syndrome symptoms including bloating, abdominal pain and loose or watery stools.

In addition, the studies found that the benefits of treatment with (brand name: Xifaxan) persisted for 10 weeks after patients stopped taking the broad-spectrum antibiotic, said Yehuda Ringel, MD, an associate professor of medicine in the UNC School of Medicine and a co-author of the studies, which are published in the Jan. 6, 2011 issue of the .

"These results support the idea that intestinal microbiota or may be an underlying cause of IBS, and altering gut bacteria by treatment with rifaximin appears to be an effective way of providing relief to those who suffer from IBS symptoms," Dr. Ringel said.

First author of the studies is Mark Pimentel, MD of Cedars-Sinai Medical Center in Los Angeles. The corresponding author is William P. Forbes, PharmD, of Salix Pharmaceuticals of Morrisville, N.C., which makes the drug and funded the studies.

The two studies, known as TARGET 1 and TARGET 2, were conducted in parallel from June 2008 through June 2009. In the studies, a total of 1,260 patients who had (IBS) without constipation were enrolled at one of 179 study sites in the U.S. and Canada. All were randomized to receive the study drug in 550 milligram doses, three times daily for two weeks, or placebo. All were then followed for an additional 10 weeks.

During the first four weeks after treatment, 40.7 percent of the patients in the rifaximin group reported adequate relief of global IBS symptoms, compared to 31.7 percent in the placebo group. Similarly, 40.2 percent in the rifaximin group had adequate relief of bloating, compared to 30.3 percent on placebo. Also, significantly more patients taking the study drug reported adequate reductions of abdominal pain and loose or watery stools.

The studies concluded that taking 550 milligram doses of rifaximin three times a day for 14 days provides better relief of IBS symptoms than placebo for up to 10 weeks after completion of therapy.

Dr. Ringel added that rifaximin, which is a semisynthetic antibiotic, has additional advantages including low systemic absorption (more than 99 percent is secreted in the stool), good antibacterial activity, low microbial resistance and a high safety profile.

"These studies support the idea that gut bacteria have an important role in maintaining normal intestinal function and emphasize the need for further research on the interaction between the intestinal microbiota and the human host," Dr. Ringel said.

Additional studies currently under way at UNC are aimed at providing a better understanding of the mechanisms by which changes in the composition of the intestinal microbiota can alter intestinal function and lead to gastrointestinal symptoms, Dr. Ringel said.

Explore further: Second bird flu case confirmed in Canada

Related Stories

Allergic disease linked to irritable bowel syndrome

Jan 30, 2008

Adults with allergy symptoms report a high incidence of Irritable Bowel Syndrome (IBS), suggesting a link between atopic disorders and IBS according to a study published this month in Annals of Allergy, Asthma & Immunology, ...

FDA OKs Amitiza for treatment of IBS-C

Apr 30, 2008

The U.S. Food and Drug Administration announced approval of Amitiza (lubiprostone) to treat constipation associated with irritable bowel syndrome.

Bacterial phylotype alterations in irritable bowel syndrome

Jan 15, 2010

Irritable bowel syndrome (IBS) is a common gastrointestinal functional disorder that can greatly affect the patient's well being. Multiple interacting mechanisms, including alterations in the intestinal microbiota, are suspected ...

Recommended for you

Ebola reveals shortcomings of African solidarity

20 hours ago

As Africa's leaders meet in Ethiopia to discuss the Ebola crisis, expectations of firm action will be tempered by criticism over the continent's poor record in the early stages of the epidemic.

Second bird flu case confirmed in Canada

Jan 30, 2015

The husband of a Canadian who was diagnosed earlier this week with bird flu after returning from a trip to China has also tested positive for the virus, health officials said Friday.

What exactly is coronavirus?

Jan 30, 2015

The conflicts in Syria and Iraq are straining public health systems and public health efforts meant to prevent and detect the spread of infectious diseases. This is generating a "perfect storm" of conditions for outbreaks. Among the infections raising concern is Middle East Respiratory Syndrome, caused by a type of coronavirus, which emerged in 2012. ...

Scientists find Ebola virus is mutating

Jan 30, 2015

(Medical Xpress)—Researchers working at Institut Pasteur in France have found that the Ebola virus is mutating "a lot" causing concern in the African countries where the virus has killed over eight thous ...

User comments : 4

Adjust slider to filter visible comments by rank

Display comments: newest first

SincerelyTwo
not rated yet Jan 05, 2011
32% from placebo, and 41% from non-placebo. I have a feeling the only way this thing works is as a placebo effect.

Assume rifaximin doesn't work, then I would expect the non-placebo group to have very similar results to the placebo group. Which seems to be the case. If it did work I would expect the non-placebo group to be at least greater than 60%. They should try and identify why it didn't work for the majority of the non-placebo group before announcing this stuff.
Quantum_Conundrum
5 / 5 (1) Jan 05, 2011
SincerelyTwo:

Didn't you see that other recent article on placebos and irritable bowel syndrome?

In the case of irritable bowel syndrome, placebos work even when the subject knows it's a placebo.

It's possible this condition is at least partly psychological, i.e. anxiety or stress related, which explains why merely "reassuring" a patient by giving them a placebo has such a drastic effect.
Ratfish
3 / 5 (2) Jan 06, 2011
Abstaining from grain is far more effective.
jsland
5 / 5 (1) Jan 06, 2011
Everything you ingest influences your gut and your gut also sends messages directly to the brain, chemically speaking. Why does the medical "industry" insist on bypassing this truth? Money. Utilitarian solutions that bypass the wholeness of the creature so that a pill becomes a solution rather than self knowledge, the exercise of will and taking responsibility inside one's body.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.